N. Zohoury replies

To the Editor:

I was pleased to read the letter by Zhang, *et al*¹ regarding our November 2017 published work, "Closing the Serological Gap in Antiphospholipid Syndrome: The Value of 'Non-criteria' Antiphospholipid Antibodies."² There are several valuable points that Zhang, *et al* bring up in their letter that I would like an opportunity to highlight and expand upon.

First, their results show significant clinical value for the IgG and IgM antiphosphatidylserine/prothrombin complex (aPS/PT) test for both diagnosing antiphospholipid syndrome (APS) and helping in risk stratification (thrombotic vs non-thrombotic). Their results showed the combination of IgG or IgM aPS/PT with lupus anticoagulant (LAC) gave a higher positive likelihood ratio compared to IgG or IgM anticardiolipin antibodies with LAC (84.84 vs 75.49) and significantly higher than IgG or IgM anti- β_2 -glycoprotein I and LAC (84.84 vs 24.72). There have been a number of studies that show the utility of aPS/PT in place of or in addition to LAC^{3,4,5} and others that show its utility as a diagnostic marker that aids in risk stratification^{6,7,8,9,10}.

Second, and possibly more significantly, I highlight their choice to categorize 12.8% of their APS population (31 out of 241) as seronegative APS. Their study is part of a growing body of evidence that continues to suggest that a significant subset of patients with APS are missed by currently accepted serological markers^{11,12}. These patients show clinical manifestations suggestive of APS but repeatedly test negative for the "criterion" markers. This subset of patients was the main focal point of our study², leading to our conclusion, similar to that of Zhang, *et al*¹³: there should be a reevaluation of the current APS criteria so that patients with true APS are not missed, helping prevent severe outcomes.

I thank the team of Zhang, *et al* for both their attention to our work and their continued efforts on this important topic. The group's result moves this field forward and contributes to improving the diagnostic approach to APS¹³. Their results broadly corroborate our publication, strengthening the evidence for the need to update the APS classification criteria. We agree that the addition of specific new markers such as aPS/PT should be considered based on the strong individual, as well as combined, performance of aPS/PT. Further, we reemphasize our suggestion that future updates to the APS classification criteria should also consider implementation of algorithms and/or scoring methods that could better evaluate patients based on an expanded antibody profile and clinical presentation.

NAVID ZOHOURY, BS, Inova Diagnostics Inc., 9900 Old Grove Road, San Diego, California 92131, USA. Address correspondence to N. Zohoury. E-mail: nzohoury@inovadx.com. Inova Diagnostics Inc. is the supplier of the kits used in the publication by Zhang, *et al*¹³. Although N. Zohoury did not personally participate in this study or have any relationship with the authors, another Inova employee was a participant in the source paper by Zhang, *et al*, referenced here¹³ and a co-author of *The Journal's* publication "Closing the Serological Gap in Antiphospholipid Syndrome: The Value of 'Non-criteria' Antiphospholipid Antibodies."²

REFERENCES

1. Zhang S, Zhang F, Li Y. Should aPS/PT be incorporated into the routine serological tests in the diagnosis of antiphospholipid syndrome? *J Rheumatol* 2019;46:114-16.
2. Zohoury N, Bertolaccini ML, Rodriguez-Garcia JL, Shums Z, Ateka-Barrutia O, Sorice M, et al. Closing the serological gap in the antiphospholipid syndrome: The value of "non-criteria" antiphospholipid antibodies. *J Rheumatol* 2017;44:1597-602.
3. Matsuda J, Saitoh N, Gotoh M, Kawasaki K, Gohchi K, Tsukamoto M. Phosphatidyl serine-dependent antiprothrombin antibody is exclusive to patients with lupus anticoagulant. *Br J Rheumatol* 1996;35:589-91.
4. Atsumi T, Ieko M, Bertolaccini ML, Ichikawa K, Tsutsumi A, Matsuura E, et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. *Arthritis Rheum* 2000;43:1982-93.
5. Heikal NM, Jaskowski TD, Malmberg E, Lakos G, Branch DW, Tebo AE. Laboratory evaluation of anti-phospholipid syndrome: A preliminary prospective study of phosphatidylserine/prothrombin antibodies in an at-risk patient cohort. *Clin Exp Immunol* 2015;180:218-26.
6. Vlasea A, Gil A, Cuesta MV, Arribas F, Diez J, Lavilla P, et al. Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential markers of antiphospholipid syndrome. *Clin Appl Thromb Hemost* 2013;19:289-96.
7. Mullen MT, Messé SR, Kasner SE, Sansing L, Husain MR, Norman GL, et al. Anti-phosphatidylserine-prothrombin antibodies are associated with outcome in a TIA cohort. *Front Neurol* 2012;3:137.
8. Sanfelippo MJ, Joshi A, Schwartz S, Meister JA, Goldberg JW. Antibodies to phosphatidylserine/prothrombin complex in suspected antiphospholipid syndrome in the absence of antibodies to cardiolipin or Beta-2-glycoprotein I. *Lupus* 2013;22:1349-52.
9. Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome a systematic review. *Thromb Haemost* 2013;111:354-64.
10. Sciascia S, Cuadrado MJ, Sanna G, Murru V, Roccatello D, Khamashta MA, et al. Thrombotic risk assessment in systemic lupus erythematosus: validation of the global antiphospholipid syndrome score in a prospective cohort. *Arthritis Care Res* 2014;66:1915-20.
11. Rodriguez-Garcia JL, Bertolaccini ML, Cuadrado MJ, Sanna G, Ateka-Barrutia O, Khamashta MA. Clinical manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called 'seronegative APS'). *Ann Rheum Dis* 2012;71:242-4.
12. Roggenbuck D, Egerer K, von Landenberg P, Hiemann R, Feist E, Burmester GR, et al. Antiphospholipid antibody profiling: time for a new technical approach? *Autoimmun Rev* 2012;11:821-6.
13. Zhang S, Wu Z, Zhang W, Zhao J, Norman GL, Zeng X, et al. Antibodies to phosphatidylserine/prothrombin (aPS/PT) enhanced the diagnostic performance in Chinese patients with antiphospholipid syndrome. *Clin Chem Lab Med* 2018;56:939-46. *J Rheumatol* 2019;46:1; doi:10.3899/jrheum.180148